Medtronic (NYSE:MDT) Rating Increased to Strong-Buy at Mizuho

Medtronic (NYSE:MDT) was upgraded by stock analysts at Mizuho to a “strong-buy” rating in a research note issued to investors on Wednesday,Zacks.com reports.

A number of other brokerages have also weighed in on MDT. Wall Street Zen upgraded Medtronic from a “hold” rating to a “buy” rating in a research note on Friday, January 23rd. William Blair raised shares of Medtronic from a “market perform” rating to an “outperform” rating in a research report on Tuesday, January 6th. Citigroup initiated coverage on shares of Medtronic in a report on Tuesday, February 3rd. They issued a “buy” rating and a $117.00 price target for the company. JPMorgan Chase & Co. dropped their price objective on shares of Medtronic from $105.00 to $100.00 and set a “neutral” rating on the stock in a report on Wednesday. Finally, Piper Sandler restated a “neutral” rating on shares of Medtronic in a research note on Monday, January 5th. One investment analyst has rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and ten have issued a Hold rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $111.05.

Medtronic Trading Down 0.9%

NYSE:MDT opened at $97.59 on Wednesday. The stock has a market capitalization of $125.10 billion, a price-to-earnings ratio of 27.18, a PEG ratio of 2.60 and a beta of 0.71. Medtronic has a 52 week low of $79.55 and a 52 week high of $106.33. The company has a quick ratio of 1.80, a current ratio of 2.42 and a debt-to-equity ratio of 0.57. The firm has a 50 day moving average of $99.10 and a 200 day moving average of $96.60.

Medtronic (NYSE:MDT) last issued its quarterly earnings data on Tuesday, February 17th. The medical technology company reported $1.36 EPS for the quarter, beating the consensus estimate of $1.34 by $0.02. Medtronic had a return on equity of 14.88% and a net margin of 13.00%.The firm had revenue of $9.02 billion during the quarter, compared to analyst estimates of $8.89 billion. During the same quarter in the prior year, the business posted $1.38 EPS. The business’s revenue for the quarter was up 5.8% compared to the same quarter last year. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS. As a group, sell-side analysts anticipate that Medtronic will post 5.46 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of the stock. Corundum Trust Company INC acquired a new position in Medtronic during the third quarter worth $27,000. Lodestone Wealth Management LLC acquired a new position in shares of Medtronic during the 4th quarter valued at about $27,000. Anfield Capital Management LLC grew its holdings in shares of Medtronic by 410.7% in the fourth quarter. Anfield Capital Management LLC now owns 286 shares of the medical technology company’s stock valued at $27,000 after purchasing an additional 230 shares during the period. Board of the Pension Protection Fund purchased a new position in Medtronic during the fourth quarter worth about $29,000. Finally, GoalVest Advisory LLC acquired a new position in Medtronic in the 4th quarter valued at about $29,000. 82.06% of the stock is currently owned by hedge funds and other institutional investors.

Medtronic News Roundup

Here are the key news stories impacting Medtronic this week:

• Positive Sentiment: Q3 beat — Medtronic reported $1.36 EPS vs. $1.34 consensus and $9.02B revenue vs. $8.89B expected; company cited robust demand for heart devices, which supports near-term earnings and the company’s FY26 guidance. Medtronic beats quarterly profit estimates on robust demand for heart devices
• Positive Sentiment: Robotics and cardiovascular growth runway — analysts (e.g., TD Cowen) continue to highlight multi‑year growth potential from cardiovascular and robotics pipelines and have reiterated buy/outperform views, supporting upside vs. peers. Medtronic: Sustained Outperformance and Multi‑Year Growth Runway
• Neutral Sentiment: Earnings call / transcript available — investors can review management’s commentary on guidance, margin outlook and device demand to assess sustainability of the beat. Medtronic (MDT) Q3 2026 Earnings Call Transcript
• Neutral Sentiment: Analyst commentary is mixed — media coverage highlights divergent analyst views on Medtronic vs. peers (e.g., Globe and Mail pieces), reflecting differing weight on growth vs. risk. Analysts Conflicted on These Healthcare Names: Masimo (MASI) and Medtronic (MDT)
• Negative Sentiment: Analysts trimmed targets and forecasts after Q3 — several firms cut price targets (JPMorgan and Baird to ~$100; Leerink and others trimmed slightly) and lowered near‑term forecasts, which reduces sell‑side upside and can pressure the stock. Medtronic Analysts Cut Their Forecasts After Q3 Earnings JPMorgan adjusts price target on Medtronic
• Negative Sentiment: Legal/competitive overhang noted — coverage of Q3 calls out a “legal hit” and competitive pressure in certain device areas; these risks can weigh on multiples until resolved. Is Mixed Q3 Results, Robotics Win and Legal Hit Altering The Investment Case For Medtronic (MDT)?

Medtronic Company Profile

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).